Research ArticleOncology
First-in-Humans Imaging with 89Zr-Df-IAB22M2C Anti-CD8 Minibody in Patients with Solid Malignancies: Preliminary Pharmacokinetics, Biodistribution, and Lesion Targeting
Neeta Pandit-Taskar, Michael A. Postow, Matthew D. Hellmann, James J. Harding, Christopher A. Barker, Joseph A. O’Donoghue, Martha Ziolkowska, Shutian Ruan, Serge K. Lyashchenko, Frank Tsai, Michael Farwell, Tara C. Mitchell, Ron Korn, William Le, Jason S. Lewis, Wolfgang A. Weber, Deepak Behera, Ian Wilson, Michael Gordon, Anna M. Wu and Jedd D. Wolchok
Journal of Nuclear Medicine April 2020, 61 (4) 512-519; DOI: https://doi.org/10.2967/jnumed.119.229781
Neeta Pandit-Taskar
1Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York
2Department of Radiology, Weill Cornell Medical College, New York, New York
3Parker Institute for Cancer Immunotherapy, Memorial Sloan Kettering Cancer Center, New York, New York
Michael A. Postow
4Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York
5Department of Medicine, Weill Cornell Medical College, New York, New York
Matthew D. Hellmann
3Parker Institute for Cancer Immunotherapy, Memorial Sloan Kettering Cancer Center, New York, New York
4Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York
5Department of Medicine, Weill Cornell Medical College, New York, New York
James J. Harding
4Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York
5Department of Medicine, Weill Cornell Medical College, New York, New York
Christopher A. Barker
6Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, New York
Joseph A. O’Donoghue
7Department of Medical Physics, Memorial Sloan Kettering Cancer Center, New York, New York
Martha Ziolkowska
1Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York
Shutian Ruan
1Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York
2Department of Radiology, Weill Cornell Medical College, New York, New York
Serge K. Lyashchenko
8Molecular Pharmacology Program, Memorial Sloan Kettering Cancer Center, New York, New York
9Radiochemistry and Molecular Imaging Probes Core, Memorial Sloan Kettering Cancer Center, New York, New York
Frank Tsai
10Honor Health, Scottsdale, Arizona
Michael Farwell
11University of Pennsylvania, Philadelphia, Pennsylvania
Tara C. Mitchell
11University of Pennsylvania, Philadelphia, Pennsylvania
Ron Korn
12Imaging Endpoints, Scottsdale, Arizona
William Le
13ImaginAb, Inc., Inglewood, California; and
Jason S. Lewis
1Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York
8Molecular Pharmacology Program, Memorial Sloan Kettering Cancer Center, New York, New York
9Radiochemistry and Molecular Imaging Probes Core, Memorial Sloan Kettering Cancer Center, New York, New York
Wolfgang A. Weber
1Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York
Deepak Behera
13ImaginAb, Inc., Inglewood, California; and
Ian Wilson
13ImaginAb, Inc., Inglewood, California; and
Michael Gordon
10Honor Health, Scottsdale, Arizona
Anna M. Wu
13ImaginAb, Inc., Inglewood, California; and
14Department of Molecular Imaging and Therapy, Beckman Research Institute of the City of Hope, Duarte, California
Jedd D. Wolchok
5Department of Medicine, Weill Cornell Medical College, New York, New York

Data supplements
Supplemental Data
Files in this Data Supplement:
In this issue
Journal of Nuclear Medicine
Vol. 61, Issue 4
April 1, 2020
First-in-Humans Imaging with 89Zr-Df-IAB22M2C Anti-CD8 Minibody in Patients with Solid Malignancies: Preliminary Pharmacokinetics, Biodistribution, and Lesion Targeting
Neeta Pandit-Taskar, Michael A. Postow, Matthew D. Hellmann, James J. Harding, Christopher A. Barker, Joseph A. O’Donoghue, Martha Ziolkowska, Shutian Ruan, Serge K. Lyashchenko, Frank Tsai, Michael Farwell, Tara C. Mitchell, Ron Korn, William Le, Jason S. Lewis, Wolfgang A. Weber, Deepak Behera, Ian Wilson, Michael Gordon, Anna M. Wu, Jedd D. Wolchok
Journal of Nuclear Medicine Apr 2020, 61 (4) 512-519; DOI: 10.2967/jnumed.119.229781
First-in-Humans Imaging with 89Zr-Df-IAB22M2C Anti-CD8 Minibody in Patients with Solid Malignancies: Preliminary Pharmacokinetics, Biodistribution, and Lesion Targeting
Neeta Pandit-Taskar, Michael A. Postow, Matthew D. Hellmann, James J. Harding, Christopher A. Barker, Joseph A. O’Donoghue, Martha Ziolkowska, Shutian Ruan, Serge K. Lyashchenko, Frank Tsai, Michael Farwell, Tara C. Mitchell, Ron Korn, William Le, Jason S. Lewis, Wolfgang A. Weber, Deepak Behera, Ian Wilson, Michael Gordon, Anna M. Wu, Jedd D. Wolchok
Journal of Nuclear Medicine Apr 2020, 61 (4) 512-519; DOI: 10.2967/jnumed.119.229781
Jump to section
Related Articles
Cited By...
- Multiparametric MRI of early tumor response to immune checkpoint blockade in metastatic melanoma
- Multiparametric MRI of Early Tumor Response to Immune Checkpoint Blockade in Metastatic Melanoma
- Imaging of T-cell Responses in the Context of Cancer Immunotherapy
- Imaging Tumor-Infiltrating Lymphocytes in Brain Tumors with [64Cu]Cu-NOTA-anti-CD8 PET
- Lymphocyte Infiltration Determines the Hypoxia-Dependent Response to Definitive Chemoradiation in Head-and-Neck Cancer: Results from a Prospective Imaging Trial
- ICAM-1 orchestrates the abscopal effect of tumor radiotherapy
- Mars Shot for Nuclear Medicine, Molecular Imaging, and Molecularly Targeted Radiopharmaceutical Therapy
- Imaging the Cancer Immune Environment and Its Response to Pharmacologic Intervention, Part 2: The Role of Novel PET Agents
- Quo Vadis, Molecular Imaging?
- Can Molecular Imaging Measure T-cell Activation?
- The PET-Tracer 89Zr-Df-IAB22M2C Enables Monitoring of Intratumoral CD8 T-cell Infiltrates in Tumor-Bearing Humanized Mice after T-cell Bispecific Antibody Treatment